How does CBD work? Mechanisms, studies and limitations
How does CBD work? Answers often consist of long lists of possible benefits. A more scientifically useful approach asks what happens biologically, what has been studied in humans and which specific outcomes have robust supporting evidence. These levels should not be confused.
Cannabidiol, abbreviated to CBD, is a cannabinoid found in the hemp plant. It is not equivalent to the characteristic THC ‘high’. However, that does not mean CBD is biologically inactive or inherently risk-free. This article moves from investigated mechanisms to selected clinical examples and their limitations.
Quick navigation: Mechanisms · Evidence of efficacy · Pharmaceutical context · Pain study · Anxiety study · Risks · Concentration and composition · Conclusion · Sources
CBD and the endocannabinoid system: no simple on–off switch
The endocannabinoid system is involved in the body's signalling processes. The frequently repeated explanation that ‘CBD simply activates CB1 and CB2 receptors’ is inadequate. CBD is investigated at several biological targets; its mode of action cannot be reduced to one receptor.
For example, a cell study by Laprairie and colleagues described CBD as a negative allosteric modulator at the CB1 receptor. Put simply, CBD changed how the receptor responded to other substances in that experimental model. This differs from turning it on like a simple switch.
The investigation explains a possible molecular relationship. On its own, it does not predict what a person will feel or whether a particular CBD oil affects a disease. Further research questions separate a cellular response from a clinically relevant effect.
What constitutes scientific evidence of efficacy?
Robust evidence relates to a clearly defined question. Relevant factors include the substance studied, its preparation, the participant group, comparison treatment and measured endpoint. ‘CBD has been researched’ is therefore not sufficient justification for any arbitrary health-related claim.
Personal accounts do not reliably answer these questions either. Symptoms can change independently of a product; expectations and other treatments may contribute. Controlled studies seek to distinguish these influences more clearly. This does not make personal experiences meaningless, but it limits their evidential value.
CBD as a pharmaceutical ingredient: a clearly defined example
One specific example of medically assessed evidence is the prescription medicine Epidyolex, whose active ingredient is cannabidiol. The European Medicines Agency describes its use as an add-on treatment for certain rare epilepsies under specified conditions and medical supervision.
This authorisation concerns the medicine tested and its defined indications. It cannot be transferred to commercially available CBD products. A shared substance name does not make different preparations, compositions and intended uses interchangeable. The medicine's authorisation therefore establishes no general promise for pain, stress or sleep problems.
CBD and pain: why the specific study result matters
A randomised, double-blind study by Pramhas and colleagues published in 2023 investigated CBD added to paracetamol for painful knee osteoarthritis. Eighty-six people were randomised. Over eight weeks, CBD showed no significant advantage over added placebo for the primary pain endpoint. More adverse events were reported with CBD.
This finding does not support recommending CBD as additional pain treatment under the conditions studied. Equally, it does not establish that every conceivable use of CBD for every cause of pain has already been conclusively assessed. Sound interpretation stays as specific as the study itself.
CBD and anxiety: a research signal is not an everyday recommendation
In a small experimental study by Bergamaschi and colleagues, 24 people with social anxiety disorder were assigned to a CBD or placebo group. Differences in subjective anxiety measures were observed during a simulated public-speaking task.
The experiment involved one situation and a small number of participants. It does not answer questions about long-term treatment, general everyday stress or arbitrary CBD products. Such a finding warrants further research, rather than a blanket promise of calming or therapeutic effects.
Non-intoxicating does not mean free of adverse effects
For the cannabidiol medicine assessed, the EMA lists possible adverse effects including sleepiness, diarrhoea and decreased appetite. Changes in liver-test results are also relevant. Medical treatment therefore considers and monitors risks and possible drug interactions.
These statements initially concern the medicine tested. They also illustrate why ‘plant-derived’ is no general guarantee of safety. Anyone taking medication or experiencing health problems should discuss cannabinoid questions with healthcare professionals. Prescribed treatment should not be independently replaced with CBD products.
Distinguishing CBD effects, concentration and composition
A percentage describes a concentration, not the strength of a clinically demonstrated benefit. CBD as a single substance, an extract and a finished product are also different things. A factual assessment therefore requires clarity about what a statement refers to.
Our article Extraction and distillation: differences for CBD explains the distinction between these manufacturing processes.
Does the source refer to CBD alone or a mixture of several ingredients?
Was the same preparation investigated as the product being discussed?
Is the subject a biological mechanism, a personal perception or a clinical endpoint?
Are risks and findings that were not confirmed also reported?
The terms full spectrum, broad spectrum and isolate describe different compositions. They do not establish a scientifically validated efficacy ranking. A laboratory report on ingredients is not clinical evidence of a health effect either.
For help interpreting ingredients, see Hemp oil, hemp seed oil and CBD oil: how to read labels.
Conclusion: CBD's effects can only be assessed in the right context
CBD has investigated biological properties and is also a subject of clinical research. Meaningful conclusions must remain tied to the particular question studied. A mechanism is not a product promise; a finding from a defined pharmaceutical context is not a general recommendation for CBD oils.
Find further background on origin and composition on our cannabidiol information page. Our article on CBN research explains how another compound is investigated in sleep studies. Discover more topics in the Parmorcan® blog.
Please note: this article provides general information and does not replace medical advice, diagnosis or treatment. It contains no recommendations for ingestion or dosage. The cited studies do not establish a health benefit of products in the Parmorcan® shop.
Sources and further evidence
The following sources are already linked in the text. The short English descriptions are provided for orientation; the original titles and bibliographic details are available in the linked publications.
Comments